{"id":56253,"date":"2023-04-26T17:06:25","date_gmt":"2023-04-26T15:06:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2023-04-26T17:06:25","modified_gmt":"2023-04-26T15:06:25","slug":"seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"
\n

\n– Long-term follow-up data for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) in advanced bladder cancer to be featured as oral presentation \u2013<\/i><\/p>\n

\n– Updated Phase 1 data on first-in-class integrin beta-6 targeted antibody-drug conjugate (ADC) (SGN-B6A) to be presented \u2013<\/i><\/p>\n

BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc.<\/a> (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023, in Chicago. Data will be presented across Seagen’s portfolio of approved medicines and pipeline agents in a range of cancer types and in earlier lines of therapy.<\/p>\n

<\/a><\/p>\n

\n\u201cSeagen has worked towards revolutionizing cancer care for 25 years by linking scientific innovation to meaningful impacts in patients\u2019 lives,\u201d said Roger Dansey, M.D., President, Research and Development and Chief Medical Officer at Seagen. \u201cOur data presented at ASCO demonstrate continued progress in our efforts to discover and develop transformative medicines.\u201d<\/p>\n

\nHighlights include new data from a robust clinical development program in bladder cancer with trials across multiple lines of treatment and into earlier stages of disease for muscle-invasive and non-muscle invasive forms of bladder cancer. Long-term follow-up data from a clinical trial of PADCEV\u00ae<\/sup> (enfortumab vedotin-ejfv) (EV-103 dose-escalation and Cohort A) will be featured in an oral presentation on Monday, June 5. The EV-103 dose-escalation\/Cohort A study is evaluating PADCEV, developed in partnership with Astellas, in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae<\/sup> (pembrolizumab) as first-line treatment in patients with locally advanced or metastatic urothelial carcinoma who are ineligible to receive cisplatin-based chemotherapy. Merck is known as MSD outside the United States and Canada.<\/p>\n

\nUpdated Phase 1 data will be presented for SGN-B6A, a wholly-owned, first-in-class vedotin ADC directed to integrin beta-6, a novel target that is highly expressed in multiple solid tumors.<\/p>\n

\nAdditionally, initial data will be presented from studies evaluating Seagen\u2019s approved medicines in potential new cancer types. Data from a Phase 2 basket study of TUKYSA\u00ae<\/sup> (tucatinib) and trastuzumab in previously treated HER2-positive metastatic biliary tract cancer will be featured in an oral presentation on Friday, June 2.<\/p>\n

\nKey data presentations for Seagen include:<\/p>\n

\nPresentations of Company-Sponsored Trials<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nAbstract Title<\/p>\n<\/td>\n

\n

\nAbstract #<\/p>\n<\/td>\n

\n

\nPresentation Time<\/p>\n<\/td>\n

\n

\nLead Author<\/p>\n<\/td>\n<\/tr>\n

\n

\nEnfortumab Vedotin<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nStudy EV-103 dose escalation\/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la\/mUC) with nearly 4 years of follow-up<\/p>\n<\/td>\n

\n

\n4505<\/p>\n<\/td>\n

\n

\nOral
\n
Monday, June 5
\n
11:30 a.m. – 2:30 p.m. CT<\/p>\n<\/td>\n

\n

\nS. Gupta<\/p>\n<\/td>\n<\/tr>\n

\n

\nEnfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202<\/p>\n<\/td>\n

\n

\n6017<\/p>\n<\/td>\n

\n

\nPoster Discussion<\/p>\n

\nMonday, June 5
\n
1:15 – 4:15 p.m. CT<\/p>\n<\/td>\n

\n

\nP. Swiecicki<\/p>\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nA first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104)<\/p>\n<\/td>\n

\n

\n4596<\/p>\n<\/td>\n

\n

\nPoster
\n
Saturday, June 3
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nA. Kamat<\/p>\n<\/td>\n<\/tr>\n

\n

\nStudy EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H<\/p>\n<\/td>\n

\n

\n4595<\/p>\n<\/td>\n

\n

\nPoster
\n
Saturday, June 3
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nT. Flaig<\/p>\n<\/td>\n<\/tr>\n

\n

\nEnfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (la\/mUC): Additional 3-month follow-up on Cohort K data<\/p>\n<\/td>\n

\n

\n4568<\/p>\n<\/td>\n

\n

\nPoster
\n
Saturday, June 3
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nT. Friedlander<\/p>\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nEV-203: Phase 2 trial of enfortumab vedotin in patients with previously treated advanced urothelial carcinoma in China<\/p>\n<\/td>\n

\n

\ne16574<\/p>\n<\/td>\n

\n

\nOnline Abstract<\/p>\n<\/td>\n

\n

\nQ. Li<\/p>\n<\/td>\n<\/tr>\n

\n

\nEnfortumab Vedotin Trials in Progress<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nKEYNOTE-905\/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC) (ENCORE)<\/p>\n<\/td>\n

\n

\nTPS4601<\/p>\n<\/td>\n

\n

\nPoster
\n
Saturday, June 3
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nA. Necchi<\/p>\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nTucatinib<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nTucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study<\/p>\n<\/td>\n

\n

\n4007<\/p>\n<\/td>\n

\n

\nOral
\n
Friday, June 2
\n
2:45 – 5:45 p.m. CT<\/p>\n<\/td>\n

\n

\nY. Nakamura<\/p>\n<\/td>\n<\/tr>\n

\n

\nReal-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer<\/p>\n<\/td>\n

\n

\n1051<\/p>\n<\/td>\n

\n

\nPoster
\n
Sunday, June 4
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nC. Anders<\/p>\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nHER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC\/ISH and NGS<\/p>\n<\/td>\n

\n

\n3528<\/p>\n<\/td>\n

\n

\nPoster
\n
Monday, June 5
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nJ. Strickler<\/p>\n<\/td>\n<\/tr>\n

\n

\nTucatinib Trials in Progress<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nHER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (trial in progress)<\/p>\n<\/td>\n

\n

\nTPS1115<\/p>\n<\/td>\n

\n

\nPoster
\n
Sunday, June 4
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nE. Hamilton<\/p>\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nMOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer (trial in progress)<\/p>\n<\/td>\n

\n

\nTPS3631<\/p>\n<\/td>\n

\n

\nPoster
\n
Monday, June 5
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nT. Bekaii-Saab<\/p>\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\nEarly-Stage\/Pipeline<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nSGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001)<\/p>\n<\/td>\n

\n

\n3024<\/p>\n<\/td>\n

\n

\nPoster
\n
Saturday, June 3
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nA. Hollebecque<\/p>\n<\/td>\n<\/tr>\n

\n

\nEarly-Stage\/Pipeline Trials in Progress<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nPhase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001: trial in progress)<\/p>\n<\/td>\n

\n

\nTPS9597<\/p>\n<\/td>\n

\n

\nPoster
\n
Saturday, June 3
\n
1:15 – 4:15 p.m. CT<\/p>\n<\/td>\n

\n

\nJ. Henry<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nPresentations of Investigator-Sponsored Trials<\/b><\/p>\n\n\n\n\n\n\n\n\n
\n

\nAbstract Title<\/p>\n<\/td>\n

\n

\nAbstract #<\/p>\n<\/td>\n

\n

\nPresentation Time<\/p>\n<\/td>\n

\n

\nLead Author<\/p>\n<\/td>\n<\/tr>\n

Enfortumab Vedotin<\/b><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Real-world use, dose intensity, and adherence to an antibody-drug conjugate (ADC) in metastatic urothelial cancer (mUC)<\/td>\n\n

\ne16567<\/p>\n<\/td>\n

\n

\nOnline Abstract<\/p>\n<\/td>\n

\n

\nR. Mamtani<\/p>\n<\/td>\n<\/tr>\n

\n

\nTucatinib<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nUCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+\/HR-, HER2+ breast cancer<\/p>\n<\/td>\n

\n

\nTPS1116<\/p>\n<\/td>\n

\n

\nPoster
\n
Sunday, June 4
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nN. McAndrew<\/p>\n<\/td>\n<\/tr>\n

\n

\nDisitamab Vedotin<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nDisitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: an open-label phase 1b\/2 study<\/p>\n<\/td>\n

\n

\n4566<\/p>\n<\/td>\n

\n

\nPoster
\n
Saturday, June 3
\n
8:00 – 11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nX. Sheng<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Seagen<\/b><\/p>\n

\nSeagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people\u2019s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com<\/a> and follow @SeagenGlobal<\/a> on Twitter.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nCertain statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of PADCEV\u00ae<\/sup> (enfortumab vedotin-ejfv), TUKYSA\u00ae<\/sup> (tucatinib), disitamab vedotin, and the company\u2019s other products and product candidates, including their potential efficacy, safety and therapeutic uses, and Seagen\u2019s pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the difficulty and uncertainty of pharmaceutical product development, including the risks that the company may experience delays in its clinical trials or otherwise experience failures or setbacks in its clinical development programs due to lack of efficacy, adverse events or other factors, and that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seagen is contained under the caption \u201cRisk Factors\u201d included in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Media<\/i>
David Caouette
\n
(310) 430-3476
\n
dcaouette@seagen.com<\/a><\/p>\n

\nFor Investors<\/i>
Douglas Maffei, Ph.D.
\n
(425) 527-4160
\n
dmaffei@seagen.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Long-term follow-up data for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) in advanced bladder cancer to be featured as oral presentation \u2013 – Updated Phase 1 data on first-in-class integrin beta-6 targeted antibody-drug conjugate (ADC) (SGN-B6A) to be presented \u2013 BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56253","6":"format-standard","7":"category-industry"},"yoast_head":"\nSeagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Long-term follow-up data for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) in advanced bladder cancer to be featured as oral presentation \u2013 – Updated Phase 1 data on first-in-class integrin beta-6 targeted antibody-drug conjugate (ADC) (SGN-B6A) to be presented \u2013 BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T15:06:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230425006159\/en\/828587\/21\/Seagen_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting\",\"datePublished\":\"2023-04-26T15:06:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\"},\"wordCount\":1248,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006159\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\",\"name\":\"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006159\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\",\"datePublished\":\"2023-04-26T15:06:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006159\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006159\\\/en\\\/828587\\\/21\\\/Seagen_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting - Pharma Trend","og_description":"– Long-term follow-up data for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) in advanced bladder cancer to be featured as oral presentation \u2013 – Updated Phase 1 data on first-in-class integrin beta-6 targeted antibody-drug conjugate (ADC) (SGN-B6A) to be presented \u2013 BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts at the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-26T15:06:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230425006159\/en\/828587\/21\/Seagen_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting","datePublished":"2023-04-26T15:06:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"},"wordCount":1248,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425006159\/en\/828587\/21\/Seagen_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/","name":"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425006159\/en\/828587\/21\/Seagen_Logo_RGB.jpg","datePublished":"2023-04-26T15:06:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230425006159\/en\/828587\/21\/Seagen_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230425006159\/en\/828587\/21\/Seagen_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/seagen-to-highlight-data-from-oncology-portfolio-and-pipeline-at-the-2023-american-society-of-clinical-oncology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56253"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56253\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}